Controls | He-pre | He-post | He-PP | APC | p value | |
---|---|---|---|---|---|---|
N | 28 | 23 | 22 | 24 | 24 | |
Age ± years | 66.7 ± 7.0 | 62.8 ± 11.7 | 66.2 ± 7.8 | 66.2 ± 8.3 | 66.9 ± 7.6 | 0.47 |
Male (%) | 22 (82) | 21 (91) | 20 (83) | 20 (83) | 21 (88) | 0.88 |
Body Mass Index | 28.4 ± 3.7 | 27.3 ± 2.7 | 26.7 ± 3.8 | 27.4 ± 3.7 | 27.7 ± 3.2 | 0.55 |
Risk factors | ||||||
Hypertension | 16 (59) | 9 (39) | 13 (57) | 10 (42) | 13 (54) | 0.52 |
Hypercholesterolemia | 6 (22) | 11 (48) | 10 (44) | 5 (21) | 14 (58) | 0.023 a |
Smoking | 13 (48) | 10 (44) | 8 (34) | 11 (46) | 10 (42) | 0.89 |
Family | 12 (44) | 9 (39) | 7 (30) | 9 (38) | 13 (54) | 0.56 |
Myocardial infarction | 7 (26) | 10 (44) | 8 (36) | 10 (42) | 8 (33) | 0.71 |
Cerebrovascular accident | 0 (0) | 0 (0) | 0 (0) | 1 (4) | 0 (0) | 0.40 |
Heart failure | ||||||
NYHA I | 20 (74) | 17 (74) | 19 (86) | 17 (71) | 16 (70) | 0.97 |
NYHA II | 2 (7) | 2 (9) | 1 (5) | 2 (8) | 3 (13) | 0.97 |
NYHA III | 5 (19) | 4 (17) | 2 (9) | 4 (17) | 4 (17) | 0.97 |
Ejection fraction | ||||||
>50 % | 21 (81) | 16 (73) | 12 (57) | 16 (67) | 19 (90) | 0.15 |
30–50 % | 5 (19) | 6 (27) | 7 (33) | 4 (17) | 1 (5) | 0.15 |
Medication | ||||||
Salicylate | 24 (86) | 19 (83) | 22 (92) | 23 (96) | 23 (92) | 0.57 |
Clopidogrel | 9 (32) | 9 (39) | 12 (50) | 9 (38) | 4 (16) | 0.15 |
Statinb | 27 (96) | 23 (100) | 24 (100) | 20 (83) | 21 (84) | 0.04 b |
Beta-blockerc | 19 (68) | 22 (96) | 24 (100) | 21 (88) | 21 (84) | 0.008 c |
ACE inhibitor | 10 (36) | 8 (35) | 10 (42) | 4 (17) | 11 (44) | 0.30 |
AT2 receptor blocker | 6 (21) | 1 (4) | 5 (21) | 5 (21) | 3 (12) | 0.40 |
Calcium channel blocker | 10 (36) | 7 (30) | 4 (17) | 10 (42) | 6 (24) | 0.35 |
Diuretics | 6 (21) | 4 (17) | 4 (17) | 7 (29) | 4 (16) | 0.77 |
Nitrates | 10 (36) | 9 (39) | 7 (29) | 12 (50) | 13 (52) | 0.43 |
Euroscore | 3 (±2) | 2 (±3) | 3 (±3) | 4 (±3) | 1 (±3) | 0.36 |